Status:

RECRUITING

Vitamin B6 Aids in Treating Inflammatory Bowel Disease

Lead Sponsor:

Changhai Hospital

Conditions:

Inflammatory Bowel Diseases

Eligibility:

All Genders

18-75 years

Phase:

NA

Brief Summary

Patients with IBD are randomized to oral administration of VitaminB6 and placebo based on the standard treatment, exploring whether VitaminB6 can increasee the clinical remission rateand improve the t...

Detailed Description

Inflammatory bowel disease (IBD) is a group of chronic idiopathic inflammatory intestinal diseases, mainly including ulcerative colitis and Crohn's disease, with increasing incidence in China and worl...

Eligibility Criteria

Inclusion

  • Patients diagnosed with IBD according to the consensus on the diagnosis and treatment of inflammatory bowel disease (Beijing, 2018, DOI: 10.19538/j.nk2018090106);
  • Have complete medical history data;
  • Volunteer to participate in this clinical trial and sign the informed consent form.

Exclusion

  • Patients with peripheral neuropathy;
  • Patients with abdominal abscess, toxic megacolon, fulminant colitis, partial colectomy, or total colectomy;
  • Patients with other autoimmune diseases, hematologic disorders, tumors, acute infections, severe liver or kidney dysfunction, severe conditions such as severe anemia, neutropenia, heart failure, organic heart disease, hepatitis B, cirrhosis, kidney disease, and psychiatric disorders;
  • Patients who have taken vitamin B6 tablets in the past 3 months;
  • Patients with a history of substance abuse;
  • Pregnant or lactating women, or those planning to become pregnant within the next 6 months;
  • Neurological disorders such as Alzheimer's disease, stroke, Parkinson's disease;
  • Participation in other clinical trials in the past 6 months;
  • Incomplete medical records (including gender, age, diagnosis, colonoscopy results, pathological diagnosis results, and other demographic data);
  • Currently taking: levodopa, phenobarbital, phenytoin sodium.

Key Trial Info

Start Date :

June 1 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 30 2025

Estimated Enrollment :

220 Patients enrolled

Trial Details

Trial ID

NCT06512441

Start Date

June 1 2024

End Date

December 30 2025

Last Update

July 22 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Changhai Hospital

Shanghai, Shanghai Municipality, China